Phacilitate Talks

Phacilitate

Welcome to Phacilitate Talks, a socially distanced chat show for the advanced therapies community, getting you close to advanced therapies experts and asking them the big questions. Get your inspiration fix straight to your inbox by becoming a Phacilitate member. Get ready to discuss, debate and deliberate today‘s most important issues... read less
ScienceScience
Life SciencesLife Sciences

Episodes

Private Equity vs Strategics with Phil Vanek and Joe LaPlume
Sep 23 2021
Private Equity vs Strategics with Phil Vanek and Joe LaPlume
The third episode of season 2 of Phacilitate Talks allows us to finally visit a financial theme as we pitch private equity against strategics…  Watch the full episode via the Phacilitate website: https://bit.ly/3nTtxy1   Welcome to the third episode of season 2 of Phacilitate Talks! This week, we are finally able to re-visit our schedule as we discuss the financial landscape advanced therapies, pitching private equity against strategics.   As we continue our journey on the road to Miami, Phacilitate Editor, Georgi Makin, and CEO of Dark Horse Consulting, Anthony Davies, invite guests to discuss key issues in the cell and gene therapy industry, asking the big questions that everyone wants the answer to.    Find out more about Advanced Therapies Week 2022: https://bit.ly/3my6QyG   IN THE BLUE CORNER…  In this episode, Anthony and Georgi are joined by Phil Vanek, CTO at Gamma Biosciences, and Joe LaPlume, Corporate Executive Vice President at Charles River Laboratories.   The group discusses how the different companies operate, the importance of financial modelling, key headlines from a year of high investment, and how the two different companies or strategies might be able to work together before ‘going shopping’ for the perfect next opportunity for investment.   QUICK LINKS  Phil Vanek: https://bit.ly/2W5g1fe  Joe LaPlume: https://bit.ly/3ksD8d0 Anthony Davies: https://bit.ly/3B7EQpJ    Christina Fuentes: https://bit.ly/2YSihaL   Georgi Makin: https://bit.ly/3jbg5Tj   The opinions expressed in this podcast are solely those of the interviewees’ and do not necessarily reflect the views or opinions of their respective employers.  This podcast has been produced in partnership with Dark Horse Consulting: https://darkhorseconsultinggroup.com/
Does AAV Have a Long Term Future? With Nicole Paulk
Sep 12 2021
Does AAV Have a Long Term Future? With Nicole Paulk
For the second episode of season 2 of Phacilitate Talks, we interrupt planned transmission to discuss the future of AAV with Nicole Paulk, following the recent FDA AdComm. Welcome to the second episode of season 2 of Phacilitate Talks! This week, we interrupt planned transmission to discuss the future of AAV following the FDA AdComm in early September. Watch the full episode via the Phacilitate website: https://bit.ly/3hrQVP3 As we continue our journey on the road to Miami, Phacilitate Editor, Georgi Makin, and CEO of Dark Horse Consulting, Anthony Davies, invite guests to discuss key issues in the cell and gene therapy industry, asking the big questions that everyone wants the answer to.  Find out more about Advanced Therapies Week 2022: https://bit.ly/3my6QyG  In this second episode, Anthony and Georgi are joined by Nicole Paulk, AAV Gene Therapy Professor at UCSF, as they discuss reactions to the AdComm meeting, and what we should expect from AAV in the future. The group discusses a perhaps unfair perception of AAV, novel technologies poised to advance the field, empty capsids, and what guidance is needed to help progress AAV. QUICK LINKS Nicole Paulk: https://bit.ly/3k65vxA Anthony Davies: https://bit.ly/3B7EQpJ Christina Fuentes: https://bit.ly/2YSihaL Georgi Makin: https://bit.ly/3jbg5Tj  The opinions expressed in this podcast are solely those of the interviewees’ and do not necessarily reflect the views or opinions of their respective employers. This podcast has been produced in partnership with Dark Horse Consulting: https://darkhorseconsultinggroup.com/
The Future of Cell and Gene Therapy with Bruce Levine and Audrey Greenberg
Aug 27 2021
The Future of Cell and Gene Therapy with Bruce Levine and Audrey Greenberg
Season 2 of Phacilitate Talks kicks off with a bang as Bruce Levine and Audrey Greenberg explore key questions associated with building capacity, acquiring talent and looking ahead in a post-pandemic world.   Welcome to season 2 of Phacilitate Talks! This season, we have left the pandemic norm and returned to offices, in-person meetings and even live events!   Watch the full video via the Phacilitate website: https://bit.ly/3kn7Naf   As we begin our journey on the road to Miami, Phacilitate Editor, Georgi Makin, and CEO of Dark Horse Consulting, Anthony Davies, invite guests to discuss key issues in the cell and gene therapy industry, asking the big questions that everyone wants the answer to.   Find out more about Advanced Therapies Week 2022: https://bit.ly/3my6QyG  In this first episode, Anthony and Georgi are joined by Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy at the University of Pennsylvania, and Audrey Greenberg, Co-Founder, Discovery Labs & Centre for Breakthrough Medicines, as they discuss the future of cell and gene therapy.   The group discusses different models for CDMO capacity expansion, acquiring appropriate talent to manage expansion opportunities and the resulting ripple effect and rapid development in the field following multiple, recent high-profile mergers and acquisitions.      *Bonus footage – “Are you talking to the FDA yet?”  As a special treat for launching the new season, we have shared an extra segment exclusive to watch on the Phacilitate website.   In this bonus clip, Anthony, Audrey and Bruce discuss the process (and best practice) for engaging the FDA in the product development pipeline for cell and gene therapies, sharing top tips and exclusive insights from their combined experience in cell and gene therapy development.   The group discusses the idea that “perfect is the enemy of good” – a quote attributed to Peter Marks (CBER, FDA) from a recent ISCT meeting – outlining key issues associated with attitudes and approaches associated with the idea of perfection with cell and gene therapies, as well as the requirements for regulating them.   Watch the bonus footage here: https://bit.ly/3krMrbI   QUICK LINKS  Bruce Levine: https://bit.ly/3DdC5oC  Audrey Greenberg: https://bit.ly/3DhDxpR  Anthony Davies: https://bit.ly/3B7EQpJ  Christina Fuentes: https://bit.ly/2YSihaL Georgi Makin: https://bit.ly/2Wg7Qgl   The opinions expressed in this podcast are solely those of the interviewees’ and do not necessarily reflect the views or opinions of their respective employers.  This podcast has been produced in partnership with Dark Horse Consulting: https://darkhorseconsultinggroup.com/